SuperworthWaters Corporation WAT
Medical - Diagnostics & Research, Healthcare
$435.99
−0.10%
- Market cap
- $42.8B
- PE
- 109×
- 10y median 29.3×
- Forward PE
- Price to sales
- 9.2×
- EV/EBIT
- 125×
- Revenue, 12 months
- $4.6B
- +52% on a year ago
- Net margin
- 3.6%
- Free cash flow yield
- 0.9%
Waters trades at 109× trailing earnings, pricier than 90% of the last ten years. Revenue was $4.6B over the last twelve months, up 52% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $819.5M | $636.8M | $708.5M | $740.3M | $872.7M+7% | $661.7M+4% | $771.3M+9% | $799.9M+8% | $932.4M+7% | $1.3B+92% | $1.6B+113% | |
| Cost of revenue | $318.4M | $261.8M | $288.2M | $301.7M | $348.5M+10% | $276.7M+6% | $321.4M+12% | $327.8M+9% | $362.9M+4% | $672M+143% | $911M+183% |
| Gross profit | $501.1M | $375.1M | $420.3M | $438.6M | $524.2M+5% | $385M+3% | $449.9M+7% | $472.1M+8% | $569.5M+9% | $595M+55% | $734M+63% |
| R&D | $44.4M | $44.6M | $46.2M | $45.3M | $46.9M+6% | $46.6M+5% | $48.5M+5% | $53.6M+18% | $46.9M+0% | $96M+106% | $122M+151% |
| SG&A | $180.4M | $174.5M | $173.2M | $169.1M | $173.3M−4% | $174.9M+0% | $201.3M+16% | $214.2M+27% | $240M+39% | $387M+121% | $405M+101% |
| $264.2M | $133.8M | $189.1M | $211.1M | $292.3M+11% | $151.7M+13% | $188.2M−1% | $192.1M−9% | $270.5M−7% | −$47M | −$86M | |
| Interest expense | $30.7M | $25.5M | $23.7M | $21.4M | $19M−38% | $14.3M−44% | $14.4M−40% | $26.6M+24% | $8.6M−55% | $48M+236% | $55M+283% |
| Pre-tax income | $237.6M | $114.9M | $169.4M | $193.6M | $277M+17% | $142.9M+24% | $177.7M+5% | $170.1M−12% | $264.2M−5% | −$88M | −$141M |
| $21.4M | $12.7M | $26.7M | $32.1M | $45.6M+113% | $21.5M+70% | $30.6M+15% | $21.2M−34% | $39M−15% | −$16M | −$5M | |
| Net income | $216.2M | $102.2M | $142.7M | $161.5M | $231.4M+7% | $121M+18% | $147M+3% | $148.9M−8% | $225.2M−3% | −$72M | −$136M |
| $3.65 | $1.72 | $2.40 | $2.71 | $3.88+6% | $2.03+18% | $2.47+3% | $2.50−8% | $3.77−3% | −$0.87 | −$1.39 | |
| 59.3M | 59.4M | 59.5M | 59.5M | 59.6M+1% | 59.7M+1% | 59.7M+0% | 59.6M+0% | 59.8M+0% | 82.1M+38% | 98.2M+65% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Waters's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $40.4B | 34.5× | 35.0× | 6.1× | +7% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .